首页> 中文期刊>中国医药 >低分子肝素钙联合盐酸氨溴索吸入治疗慢性阻塞性肺疾病急性加重期疗效分析

低分子肝素钙联合盐酸氨溴索吸入治疗慢性阻塞性肺疾病急性加重期疗效分析

摘要

目的 观察低分子肝索钙与盐酸氨溴索联合吸入治疗慢性阻塞性肺疾病急性发作期(AECO-PD)的疗效.方法 46例AECOPD患者按照就诊顺序分为治疗组24例,对照组22例,对照组患者给予β2-受体激动剂、茶碱类药物、抗生素、糖皮质激素、活血化瘀、吸氧等常规治疗,治疗组在常规治疗基础上加用低分子肝素钙2500 IU加生理盐水5 ml,盐酸氨溴索注射剂30 mg加生理盐水10 ml,均2次/d,雾化吸入,比较2组患者临床症状的改善情况、平均住院13等指标.结果 2组患者治疗7 d后动脉血氧分压、二氧化碳分压及呼气峰流量均较治疗前明显改善(P<0.01),治疗组平均住院时间为(10±4)d,对照组(14±4)d,组间比较差异有统计学意义(P<0.05).结论 低分子肝素钙联合盐酸氨溴索吸入治疗AECOPD,临床疗效较好.%Objective To investigate the effect of low-molecular-weight heparin calcium combined with am-broxol on acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Forty-six patients were divided into the treatment group (n = 24)and control group (n = 22 ). In the treatment group, the low-molecu-lar-weight heparin calcium and ambroxol were added in therapy, the other drugs used in the therapy were same in both groups. Results After treatment, arterial oxygen pressure, cardoon dipjide partial pressure and peak expirato-ry flow of all patients were significantly improved(P <0.01 ). The average hospitalization of treatment group [(10±4) d] was shorter than control group [(14 ± 4) d] (P < 0.05 ). Conclusion The inhalation treatment of AECOPD combined with low-molecular-weight heparin Calcium and ambroxol is superior to conventional therapy.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号